Andy Hu, MD

Andy brings diverse experience in corporate finance, strategy, and business development across the life sciences industry. Before joining Augustine, Dr. Hu was Chief Business Officer of Arkuda Therapeutics, a biotech company focused on neurodegenerative diseases which was acquired by Johnson & Johnson and announced in January 2025. Previously, Dr. Hu was Senior Vice President, Business Development at Dimension Therapeutics, where he was a leader of teams that successfully brought the company through an IPO, several strategic partnering transactions, and ultimately an acquisition by Ultragenyx. Dr. Hu also previously worked as part of the investment banking team at Leerink Partners, where he was part of teams that successfully executed over $600 million in equity financings for public and private life sciences companies, and as a senior consultant at Strategic Decisions Group, where he led strategic consulting engagements for several of the world’s largest biopharma companies. Dr. Hu received his AB in Environmental Science and Public Policy from Harvard University, an M.D. from Baylor College of Medicine, and an MBA from the Jones Graduate School of Management at Rice University.